The drug was found to safely preserve the body s insulin production and suppress the advancement of type 1 diabetes when initiated within 100 days of diagnosis.
Based on the Likert scale, most patients with atopic dermatitis (AD) using baricitinib reported being either “satisfied” (76%) or “very satisfied” (18%).